Last week took place the agreement ceremony between the Bellvitge Biomedical Research Institute (IDIBELL) and Shenzhen Bay Laboratory (SBZL) to create a joint predoctoral researchers exchange program. This international initiative wants to encourage the completion of stays in both centers by researchers in the early stages of their careers. Its objective is to complement the training of these professionals in regenerative medicine through experience in a high-level center.
The new program, following IDIBELL’s strategic plan, aims to promote interaction between both institutions and reinforce scientific collaboration.
At the event, Dr. Gabriel Capellá, director of IDIBELL, and Dr. Yun-Dong WU, executive deputy director of SBZL, showed their satisfaction and highlighted the enrichment opportunity that this program represents. Dr. Xinhao Zhang and Dr. Ángel Raya, coordinator of the Regenerative Medicine program and promoter of the initiative at IDIBELL, explained the details of the project and how it will be carried out.
The program contemplates the mobility of 5-10 students per year who will carry out stays of at least 6 months. All of them will be supervised by two responisbles, one from each center, who will ensure the professional and personal success of the stay.
This new exchange program will have a supervision committee with representation from both institutions, which will select the best candidates and coordinate the initiative. All this is to ensure maximum use of the exchange program and forge new connections and collaborations that add value to both institutions.
The Shenzhen Bay Laboratory
Shenzhen Bay Laboratory is an established center in Guangdong-Hong Kong-Macao Greater Bay Area promoted by the city of Shenzhen and Peking University. The center plays a very important role in the development of the region since it acts as the central axis of the health sciences. The SZBL combines the intellectual potential of the region with the advanced techniques available to conduct high-quality research.
The Chinese center carries out cross-sectional biomedical research aimed at the prevention and control of diseases such as cancer, metabolic syndromes, cardiovascular or neurodegenerative diseases.
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center aimed at improving people’s health. It carries out high-level basic and clinical research organized in four thematic areas: cancer, neurosciences, translational medicine, and regenerative medicine. Research, innovation, and society are the pivots on which researchers work daily to improve the quality of life of citizens.
IDIBELL has its own researchers and integrates the research carried out at the Bellvitge University Hospital, the Viladecans Hospital, the Catalan Institute of Oncology in Hospitalet, and the University of Barcelona on the Bellvitge Campus.
The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center created in 2004. It is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L’Hospitalet de Llobregat.
IDIBELL is a member of the Campus of International Excellence of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the “HR Excellence in Research” program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Center of the AECC Scientific Foundation (FCAECC).